Profile of Drug-Resistant Tuberculosis Patients at the Haji Regional Hospital, East Java Province in 2019-2022

Authors

  • Meddy Setiawan Fakultas Kedokteran Universitas Muhammadiyah Malang
  • Raditya Widya Surianata Fakultas Kedokteran Universitas Muhammadiyah Malang
  • Yolla Gitamaya Yustikasari Fakultas Kedokteran Universitas Muhammadiyah Malang
  • Ridho A'bid Permana Fakultas Kedokteran Universitas Muhammadiyah Malang
  • Nurani Hakiki Fakultas Kedokteran Universitas Muhammadiyah Malang
  • Annisa Brilian Ornadi Fakultas Kedokteran Universitas Muhammadiyah Malang

Abstract

Objective: To determine the profile of TB cases that are resistant to antibiotics and the resistance pattern of Mycobacterium tuberculosis in patients at Haji Regional Hospital, East Java Province 

Method: The type of research is descriptive-retrospective based on primary data from patient medical records and laboratories in the 2019-2022 period 

Results: The results show that the incidence of drug resistance based on the most OAT in Tuberculosis Drug Resistant Patients at the Haji Hospital of East Java Province in 2019-2022 is a combination of R+H as many as 69 patients (46%) and the origin of the most infection is relapse / recurrence of 73 patients (48.7%) 

Conclusion: According to the characteristics, the majority of drug-resistant tuberculosis patients at Haji Hospital in East Java Province from 2019-2022 were male patients aged 19-59 years. According to the resistance pattern of M. tuberculosis bacteria, the most common type of drug resistance was MDR-TB (Multi-Drug Resistant Tuberculosis), and the most previous TB history was relapsed patients. 

 

Downloads

Download data is not yet available.

References

Adigun R, Singh R. Tuberculosis. [Updated 2023 Jul 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK441916/

Ali, Monadil H., Alian A. Alrasheedy, Mohamed Azmi Hassali, Dan Kibuule, and Brian Godman. (2019). "Predictors of Multidrug-Resistant Tuberculosis (MDR-TB) in Sudan" Antibiotics 8, no. 3: 90. https://doi.org/10.3390/antibiotics8030090

Chen, Q., Peng, L., Xiong, G., Peng, Y., Luo, D., Zou, L., & Chen, K. (2019). Recurrence Is a Noticeable Cause of Rifampicin-Resistant Mycobacterium tuberculosis in the Elderly Population in Jiangxi, China. Frontiers in public health, 7, 182. https://doi.org/10.3389/fpubh.2019.00182

Coleman M, Martinez L, Theron G, Wood R, Marais B. Mycobacterium tuberculosis Transmission in High-Incidence Settings-New Paradigms and Insights. Pathogens. 2022;11(11):1228. Published 2022 Oct 25. doi:10.3390/pathogens11111228

Fajriah Saraswati, Murfat Z, Rasfayanah, Wiriansya EP, Akib MN., Rusman, et al. (2022). Karakteristik Penderita Tuberkulosis Paru Yang Relaps Di RS Ibnu Sina Makassar. Fakumi Med J J Mhs Kedokt 2(5):319–28. https://doi.org/10.33096/fmj.v2i5.8

KEMENKES. (2023). Laporan Program Penanggulangan Tuberkulosis Tahun. Jakarta: Kementerian Kesehatan RI. 2023.

Merzistya, A., & Rahayu, S. R. (2019). Kejadian Putus Berobat Penderita Tuberkulosis Paru. Higea Journal of Public Health Research and Development, 298-310.

Seung KJ, Keshavjee S, Rich ML. Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis. Cold Spring Harb Perspect Med. 2015;5(9):a017863. Published 2015 Apr 27. doi:10.1101/cshperspect.a017863

Siregar,S,R. (2019). Extensively Drug Resistant Tuberculosis (XDR TB).Jurnal Averrous. 5(2): 26-43.

Tobin EH, Tristram D. Tuberculosis. [Updated 2024 Mar 20]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK441916/

Wahidah I, Arwi KM, Norcahyanti I, Dewi IP, Aryani DE, Machlaurin A. (2024). Determinan pola resistensi pasien Multi-Drug Resistant Tuberculosis (MDRTB) : Studi Multi-Center di Jember, Indonesia 4(1):56–67. https://doi.org/10.37311/ijpe.v4i1.24636

WHO. (2023). Global Tuberculosis Report 2022. Geneva: World Health Organization.

Published

2024-07-27

Issue

Vol. 20 No. 1 (2024): June 2024

Section

Article

License

Copyright (c) 2024 Meddy Setiawan, Raditya Widya Surianata, Yolla Gitamaya Yustikasari, Ridho A'bid Permana, Nurani Hakiki, Annisa Brilian Ornadi

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-ShareAlike 4.0 International License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).


 Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.